Navigation Links
Angelman syndrome deficits rescued in mice

Children with Angelman syndrome are often seen laughing and smiling, but this cheerful demeanor masks serious neurological problems ?mental retardation, movement problems and seizures.


ew research in mice, however, suggests that many of these deficits could be alleviated.

Edwin Weeber, Ph.D., and colleagues reversed the neurological deficits in a mouse model of Angelman syndrome by preventing the inhibition of CaMKII, an enzyme highly expressed in brain regions affected by Angelman syndrome.

The results, which appear in the March issue of Nature Neuroscience (currently available online), reveal an important part of the mechanism underlying the condition and point to potential therapeutic targets for treating these symptoms.

Angelman syndrome, which affects approximately one in 15,000 children, is a debilitating neurological disorder characterized by mental retardation, severely limited speech, and movement and balance problems.

In 1997, researchers determined that Angelman syndrome was caused by a mutation in a single gene, called UBE3A. They subsequently developed a mouse model of Angelman syndrome by mutating this gene.

But the finding was baffling, said Weeber, because UBE3A is a "housekeeping" gene, meaning that it broadly regulates cellular processes not particularly specific for any of the neurological deficits seen in these children. Specifically, the protein encoded by UBE3A "tags" other proteins for degradation by the cellular "garbage disposal," the proteasome.

"The most difficult thing to rationalize was that this housekeeping gene ?which nobody thought did anything ?caused severe mental retardation," said Weeber, an assistant professor of Molecular Physiology and Biophysics and Pharmacology and senior author on the study.

"So we started trying to identify some of the protein's molecular targets."

In the process, Weeber and colleagues identified an abnormality i n the Angelman syndrome mouse model ?changes in an enzyme called calcium/calmodulin-dependent protein kinase II (CaMKII), which is important in the cellular processes that underlie learning and memory.

They found that, in Angelman syndrome, CaMKII activity was reduced due to an inhibitory chemical modification (phosphorylation). Because of CaMKII's prominent role in neuronal function, Weeber suspected that this might account for many of the neurological deficits seen in Angelman syndrome children.

Fortuitously, one of Weeber's colleagues ?Ype Elgersma, Ph.D., at Erasmus Medical Center in Rotterdam, Netherlands ?had created a mouse with a mutation that prevented this inhibition of CaMKII.

The researchers decided to breed the Angelman mice with the CaMKII mutant mice to see if counteracting the CaMKII inhibition would alleviate the neurological problems.

The researchers then ran the resulting "double mutants" through a battery of neurological and cognitive tests.

Angelman mice performed poorly on learning and memory tasks and displayed impaired motor coordination.

The double mutants, however, showed normal learning and memory and motor coordination. And while the Angelman mice were also prone to seizures, the double mutants showed very low seizure susceptibility.

Weeber was surprised by the robust results. "We thought we might rescue some of the deficits that we saw in the mouse model," he said. "We had no idea that we were going to rescue basically everything."

Although impossible to apply the genetic engineering used in the current study to correct these deficits in mice to humans, Weeber thinks that the findings may point to new therapeutic targets for the disorder.

"It's very conceivable that if we can figure out what lies between UBE3A and CaMKII ?and if it's a specific path ?then that could be a therapeutic target."

But the results may apply more broadly, Weeber s aid, to other types of mental retardation syndromes that remained unexplained and untreatable.

"There are a lot of mental retardation syndromes that we still don't understand. Maybe the changes in CaMKII associated with Angelman syndrome could be implicated in other mental retardation syndromes as well."


'"/>

Source:Vanderbilt University Medical Center


Related biology news :

1. 15-year hunt finds cause of pseudothalidomide syndrome
2. Gene for immune deficiency syndromes found
3. Removing DNA repair gene causes metabolic syndrome
4. Congenital rubella syndrome nearly eradicated in the US
5. Researchers link two more genes to sudden infant death syndrome
6. Down syndrome: Its not just the age factor
7. A potential biological cause for sudden infant death syndrome
8. Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows
9. Chronic fatigue syndrome impairs a persons slow wave activity during sleep
10. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
11. Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/9/2017)... ... , ... The award-winning American Farmer television series will feature 3 Bar Biologics ... at 8:30aET on RFD-TV. , With global population estimates nearing ten billion people ... to feed a growing nation. At the same time, many of our valuable resources ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring ... kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using ...
Breaking Biology Technology: